Scribe Therapeutics Moves Toward Nasdaq Debut as CRISPR Pipeline Advances Into Clinic

The in vivo gene editing biotech has announced IPO plans as it pushes its lead PCSK9 programme into first-in-human trials. Scribe Therapeutics has announced plans for an initial public offering on the Nasdaq, marking a significant step for the CRISPR-focused biotech as it transitions from platform development into early clinical execution.

The company did not disclose pricing terms for the proposed share sale, which will serve as an early test of investor appetite for pre-commercial gene editing platforms.

A More Crowded IPO Window in 2026

The announcement comes during a resurgence in biotech IPO activity in 2026, with several high-profile listings from companies such as Parabilis Medicines, Kailera Therapeutics, Generate:Biomedicines, and Kardigan.

However, most of those entrants are backed by later-stage clinical assets. Scribe’s IPO is notable for arriving at a comparatively earlier stage of development, with its lead programme only recently cleared to enter human trials.

Building In Vivo CRISPR Therapies

Founded in 2017, Scribe Therapeutics is focused on developing engineered in vivo CRISPR-based genetic medicines designed for durable therapeutic effects without permanent DNA alteration.

Its lead programme, STX-1150, is being developed for hypercholesterolaemia and targets the PCSK9 gene, a key regulator of LDL cholesterol levels.

The therapy combines:

• mRNA encoding a highly engineered epigenetic long-term X-repressor (ELXR)

• A single guide RNA targeting PCSK9

• A liver-targeted lipid nanoparticle delivery system
  

The goal is a single-dose treatment that epigenetically silences PCSK9 in liver cells, potentially delivering long-term LDL-C reduction without permanent genome modification.

First-in-Human Trials Underway

In May 2026, Scribe received clearance from the Australian Therapeutic Goods Administration to begin a Phase I clinical trial of STX-1150.

The study will evaluate up to 64 adults with elevated LDL cholesterol and increased cardiovascular risk, with trial sites across Australia and New Zealand.

The company’s broader pipeline includes:

• STX-1200 for elevated lipoprotein(a)

• STX-1400 for severe hypertriglyceridaemia and familial chylomicronaemia syndrome
  

IPO Funding to Expand Pipeline

Proceeds from the planned IPO are expected to support advancement of STX-1150 into later-stage development, as well as continued investment in earlier pipeline assets and CRISPR platform expansion.

The funding will also help accelerate Scribe’s broader ambition to build a diversified portfolio of in vivo gene editing therapies targeting cardiometabolic disease.

Strategic Partnerships Strengthen Platform Reach

Alongside internal development, Scribe has established multiple partnerships with major pharmaceutical companies.

These include collaborations with Eli Lilly, focused on applying its CRISPR X-Editing (XE) technologies to neurological and neuromuscular disorders, as well as two separate agreements with Sanofi, the most recent of which explores in vivo genetic medicines including potential applications in sickle cell disease.

Summary

Scribe Therapeutics has announced plans to list on the Nasdaq as it advances its CRISPR-based gene editing pipeline into clinical development.

With its lead PCSK9-targeting programme now in Phase I trials and multiple cardiometabolic and genetic disease assets in development, the IPO will test investor confidence in early-stage in vivo gene editing platforms amid a renewed wave of biotech public offerings.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com